Regulatory milestone sets the tone for COMPASS Pathways stock

The latest move in COMPASS Pathways (CMPS) stock is closely tied to the FDA granting a rolling New Drug Application review and selecting COMP360 for the Commissioner's National Priority Voucher program in treatment resistant depression.

Against the backdrop of this FDA progress, COMPASS Pathways’ 55.6% 1 month share price return and 37.6% year to date share price return contrast with a much longer term 5 year total shareholder return of a loss of 73.6%. This suggests momentum has recently picked up after a difficult stretch.

If this kind of regulatory driven move has your attention, it can be a good moment to widen your watchlist and check out 33 healthcare AI stocks

With COMPASS Pathways now valued at about US$1.2b and trading at US$9.01, recent returns and a large intrinsic discount raise a simple question: is this a genuine opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 58.9% Undervalued

On the most followed narrative, a fair value of about $21.92 sits well above the last close at $9.01, putting a lot of weight on what COMP360 could become if the current clinical and regulatory path holds.

Completion of enrollment in the COMP006 Phase III trial and the plan to use 9 week data from Part A together with 26 week COMP005 data to support a rolling NDA process could shorten the path to potential approval, which would bring revenue forward and may support earlier earnings visibility.

Curious what justifies that kind of gap between price and narrative fair value? The heart of it is a long term revenue build, margin lift from biotech like levels and a future earnings multiple that assumes COMP360 secures a meaningful role in treatment resistant depression and beyond.

Result: Fair Value of $21.92 (UNDERVALUED)

However, this hinges on clinical success and FDA approval. Any delay or weaker-than-expected data could force extra financing that dilutes shareholders and pressures the story.

Next Steps

With both risks and rewards in play, does the current mood around COMPASS Pathways match your own view, or are you seeing something different? If you want to move quickly and ground your stance in the same data other investors are watching, take a closer look at the 1 key reward and 5 important warning signs

Ready for more investment ideas?

If COMPASS Pathways is on your radar, do not stop there. Broaden your opportunity set now, or risk missing other stocks that better fit your goals.

• Target quality at a discount by scanning companies that combine strong fundamentals with attractive valuations using the 50 high quality undervalued stocks.
• Prioritise resilience and sleep easier at night by focusing on businesses highlighted in the 70 resilient stocks with low risk scores.
• Spot tomorrow's potential standouts early by searching lesser known names with solid numbers using the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.